Most recent update: Sunday, April 29, 2018 - 14:56

You are here

CVD prevalence

CVD afflicts 175 million and over 3 million have VU in the US

US prevalence and incidence and costs of chronic venous disease, varicose veins and venous ulcers

According to a new report published by The Sage Group, 175 million U. adults suffer from CVD and over three million have venous ulcers. CVD represents a spectrum of medical conditions involving morphological and functional abnormalities of the venous system. Severity ranges from mild disease characterised by spider veins, reticular veins and telangiectasia to active venous ulcers.

 “Chronic venous disease afflicts almost twice as many people as all cardiovascular diseases combined, and six times more than those with diabetes. It is one of our most prevalent chronic diseases. However, CVD is significantly underestimated, underdiagnosed and undertreated,” said Mary L Yost, President of The Sage Group. “Our venous disease estimates are higher than most of the commonly quoted numbers. Research on US epidemiology is sparse. Our review of the literature concluded that many of the frequently quoted, older studies have significant limitations. This is especially true for venous ulcers with widely varying incidence and prevalence estimates. Prevalence and incidence of venous ulcers is frequently underestimated because approximately half of patients self-treat.”

According to The Sage Group, the report contains a comprehensive analysis of the peer-reviewed literature published on epidemiology, costs and consequences of chronic venous disease. CVD, defined as CEAP classifications C0-C6, ranges in severity from no visible or palpable signs of disease to active venous ulcers. The analysis focuses on varicose veins (C2) and the more severe forms of the disease, chronic venous insufficiency or CVI (C3-C6), especially venous ulcers (C5-C6).

One of the primary purposes of the report is to estimate the current US prevalence and incidence of varicose veins, CVI and venous ulcers.  The Sage Group’s estimates are based on conclusions reached after a thorough review of all studies containing percentage prevalence and incidence data. Varicose veins, CVI and venous ulcers are estimated based on the 2015 US population combined with the most reasonable and appropriate percentage prevalence and incidence data.

The report contains a comprehensive analysis of the peer-reviewed literature published on epidemiology, costs and consequences of chronic venous disease. US.prevalence and incidence of CVD, varicose veins, chronic venous insufficiency (CVI) and venous ulcers is estimated. Current economic costs of these diseases are quantified.

Its prevalence dwarfs other chronic diseases including peripheral artery disease (20 million), diabetes (29 million) and all cardiovascular diseases combined (86 million). Despite this CVD is underestimated, underdiagnosed and undertreated.

Another primary purpose of the report is to quantify the current economic impact of chronic venous disease, especially venous ulcers. It appears that these costs have frequently been underestimated. This reflects the fact that the majority of quoted U.S. CVD cost estimates are based on 1980s European cost studies, as well as lower incidence and prevalence numbers. Because of differences in clinical practice, reimbursement systems and prices, costs cannot be compared across countries. The Sage Group’s economic estimates employ U.S. data with all costs inflated to 2015 dollars.

“The costs of venous disease represent a significant burden on the economy and on patients. Venous ulcers alone cost US$21 to US$46 billion annually,” she added.  “Our cost estimates vastly exceed the commonly quoted range of US$1.5-US$3.0 billion. Among other reasons, this difference reflects the fact that these older estimates were based on substantially lower ulcer incidence and on 1980s cost data from the UK and Sweden.”